Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
16h
Stockhead on MSNHealth Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agentBrazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix. ... Read ...
In a report released today, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a ...
5d
Pharmaceutical Technology on MSNTelix’s new lead-212 generator could dispel medical isotope scalability hurdlesLead-212 is a promising radioactive isotope for use in targeted alpha therapy, an alternative modality to beta-particle-based ...
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...
William Blair restated their outperform rating on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) in a research note released on Wednesday ...
The marketing authorization is granted to Telix’s partner R2PHARMA, Brazil’s leading cold kit manufacturer, nuclear pharmacy and cyclotron network, and a subsidiary of GSH Corp Participações S.A.
The high-flying S&P/ASX 200 Index (ASX: XJO) share made a major acquisition announcement. Here’s what you need to know.
(MENAFN- GlobeNewsWire - Nasdaq) MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results